Advertisements impact the physiological efficacy of a branded drug

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 32, 2013, Pages 12931-12935

  Kamenica, Emir ^a   Naclerio, Robert ^b   Malani, Anup ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Advertising; Placebo effect

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; LORATADINE;

ADULT; ALLERGY; ARTICLE; AUDIOVISUAL EQUIPMENT; DRUG EFFICACY; DRUG MARKETING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TELEVISION; URTICARIA;

ADVERTISING; PLACEBO EFFECT;

ADULT; ADVERTISING AS TOPIC; CETIRIZINE; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPERSENSITIVITY; LORATADINE; MALE; TELEVISION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881411113     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1012818110     Document Type: Article

References (31)

1. PhRMA (2008) The facts about pharmaceutical marketing and promotion. Available at http://phrma.org/sites/default/files/pdf/marketing-and-promotion- facts-071108-final.pdf. Accessed June 24, 2013.
2. Nelson HS (2001) Variables in allergy skin testing. Immunol Allergy Clin North Am 21(2):281-290.
3. Malani A (2006) Identifying Placebo Effects with Data from Clinical Trials. J Polit Econ 114(2):236-256.
4. Malani A, Houser D (2008) Expectations mediate objective physiological placebo effects. Advances in Health Economics and Health Services Research, pp 311-327.
5. Hashish I, Hai HK, Harvey W, Feinmann C, Harris M (1988) Reduction of postoperative pain and swelling by ultrasound treatment: A placebo effect. Pain 33(3):303-311.
6. Wager TD, et al. (2004) Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303(5661):1162-1167.
7. Hróbjartsson A, Gøtzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344(21):1594-1602.
8. de Craen AJM, Roos PJ, Leonard de Vries A, Kleijnen J (1996) Effect of colour of drugs: Systematic review of perceived effect of drugs and of their effectiveness. BMJ 313(7072):1624-1626.
9. Branthwaite A, Cooper P (1981) Analgesic effects of branding in treatment of headaches. Br Med J (Clin Res Ed) 282(6276):1576-1578.
10. Waber RL, Shiv B, Carmon Z, Ariely D (2008) Commercial features of placebo and therapeutic efficacy. JAMA 299(9):1016-1017.
11. Shiv B, Carmon Z, Ariely D (2005) Placebo effects of marketing actions: Consumers may get what they pay For. J Mark Res 42(4):383-393.
12. Plassmann H, O'Doherty J, Shiv B, Rangel A (2008) Marketing actions can modulate neural representations of experienced pleasantness. Proc Natl Acad Sci USA 105(3): 1050-1054.
13. McClure SM, et al. (2004) Neural correlates of behavioral preference for culturally familiar drinks. Neuron 44(2):379-387.
14. Lucchiari C, Pravettoni G (2012) The effect of brand on EEG modulation: A study on mineral water. Swiss J Psychol 71(4):199-204.
15. Bagwell K (2007) The economic analysis of advertising. Handbook of Industrial Organization, eds Armstrong M, Porter R H (Elsevier, Amsterdam), Vol 3 pp 1701-1844.
16. Braithwaite D (1928) The economic effects of advertisement. Econ J 38(149):16-37.
17. Galbraith JK (1958) The Affluent Society (Houghton Miflin, Boston); reprinted (1998) (Houghton Mifflin Harcourt).
18. Nelson P (1974) Advertising as information. J Polit Econ 82(4):729-754.
19. Butters GR (1977) Equilibrium distributions of sales and advertising prices. Rev Econ Stud 44(3):465-491.
20. Milgrom P, Roberts J (1986) Price and advertising signals of product quality. J Polit Econ 94(4):796-821.
21. Stigler GJ, Becker GS (1977) De gustibus non est disputandum. Am Econ Rev 67(2): 76-90.
22. Becker GS, Murphy KM (1993) A simple theory of advertising as a good or bad. Q J Econ 108(4):941-964.
23. McEwen BS, Underhill LH, McEwen BS (1998) Protective and damaging effects of stress mediators. N Engl J Med 338(3):171-179.
24. Nielsen/Wolters Kluwer Health (2008) Consumer behavior and managed care: Impact of the Zyrtec Rx-to-OTC switch. Available at http://download.lww.com/ wolterskluwer-vitalstream-com/PermaLink/Allergy-whitepaperFinal.pdf. Accessed June 24, 2013.
25. Gellad ZF, Lyles KW (2007) Direct-to-consumer advertising of pharmaceuticals. Am J Med 120(6):475-480.
26. Whalen J (December 11, 2008) Europe moves to loosen ban against drug ads. The Wall Street Journal, Section B, p 4.
27. Gilbody S, Wilson P, Watt I (2005) Benefits and harms of direct to consumer advertising: A systematic review. Qual Saf Health Care 14(4):246-250.
28. Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG (2003) Demand Effects of Recent Changes in Prescription Drug Promotion, Forum for Health Economics & Policy (Berkeley Electronic Press), Vol 6.
29. Clark MJ, Million RP (2009) Allergic rhinitis: Market evolution. Nat Rev Drug Discov 8(4):271-272.
30. Harris G (March 22, 2002) As blockbuster Claritin goes generic, Schering-Plough pushes a close sibling. The Wall Street Journal, Section A, p 1.
31. Zachry WM, 3rd, et al. (2002) Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. Am J Health Syst Pharm 59(1):42-49.